Assumption of Licensor Position in mRNA-based ERA Technology (Contract with HanAll BioPharma)
- Company won auction for Turn Bio's assets, assuming licensor status and all rights/obligations in the joint development and license agreement for mRNA ERA platform technology with HanAll BioPharma
- Total deal value up to USD 239M (upfront USD 1M non-refundable; development/regulatory/sales milestones USD 238M; royalties separate) - variable upon achievement
- Conditional contract: revenue recognition depends on clinical and regulatory success; risk of termination due to regulatory hold or failure
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Major Management Matters Related to Investment Judgment (Succession of Status of Technology Transfer Agreement for mRNA-based Epigenetic Reprogramming of Aging (ERA))
- Company: Daewoong Pharma (069620)
- Submission: Daewoong Pharma
- Receipt: 05-07-2026
- Under KRX KOSPI Market Division